Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.67 |
| ▸ | TSPO | P30536 | 1/20 | 0.67 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.67 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.33 |
| ▸ | UGCG | Q16739 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607501 | 0.85 | GRM5 (0.84) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607521 | 0.85 | GRM5 (1.00) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608631 | 0.85 | GRM5 (0.75) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609908 | 0.83 | GRM5 (0.77) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607815 | 0.82 | GRM5 (0.77) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609825 | 0.81 | GRM5 (0.75) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609274 | 0.81 | GRM5 (0.75) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608379 | 0.80 | GRM5 (1.00) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL29355575 | 0.80 | GRM5 (1.00) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| Basimglurant SCHEMBL560590 | 0.79 | GRM5 (1.00) | GRM5KCNH2ADRB3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216789-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN LA ROCHE (CH) | 2019-07-18 | — | — | US | claimed |
| US-20170202819-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | F. HOFFMANN-LA ROCHE AG | 2017-07-20 | — | — | US | claimed |
| US-20150140087-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN-LA ROCHE INC. | 2015-05-21 | — | — | US | claimed |
| EP-2808022-A1 | Pharmaceutical compositions of metabotropic glutamate 5 receptor (MGLU5) antagonists | F. Hoffmann-La Roche AG (CH) | 2014-12-03 | — | — | EP | claimed |
| US-8293916-B2 | Diazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | claimed |
| US-20120040008-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | CHATTERJI ASHISH (US) | 2012-02-16 | — | — | US | claimed |
| US-20120039999-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | CHATTERJI ASHISH (US) | 2012-02-16 | — | — | US | claimed |
| JP-4690395-B2 | — | — | 2011-06-01 | — | — | JP | claimed |
| US-20100048569-A1 | DIAZOLE DERIVATIVES | BUETTELMANN BERND | 2010-02-25 | — | — | US | claimed |
| US-20090054490-A1 | METHODS FOR THE TREATMENT OF GERD WITH MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | US | claimed |
| WO-2009024491-A1 | USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GERD | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | claimed |
| EP-1756086-B1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | claimed |
| EP-1756086-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | claimed |
| US-20060030559-A1 | Diazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | claimed |
| WO-2005118568-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | claimed |
| US-20250073216-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN LA ROCHE (CH) | 2025-03-06 | — | — | US | disclosed |
| US-20220241260-A9 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN LA ROCHE (CH) | 2022-08-04 | — | — | US | disclosed |
| US-20090054490-A1 | METHODS FOR THE TREATMENT OF GERD WITH MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | US | disclosed |
| EP-1756086-B1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-20060030559-A1 | Diazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048569-A1 | DIAZOLE DERIVATIVES | GRM1, GRM2, GRIN2B | GRM5 14/4885KCNH2 551/4885ADRB3 1151/4885 |
| US-20060030559-A1 | Diazole derivatives | GRM1, GRM2, GRIN2B | GRM5 14/4885KCNH2 551/4885ADRB3 1151/4885 |
| US-20120040008-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
| US-20190216789-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1493/4885ADRB3 3062/4885 |
| US-20170202819-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
| US-20090054490-A1 | METHODS FOR THE TREATMENT OF GERD WITH MGLUR5 ANTAGONISTS | GRM5, HRH2, GRPR | GRM5 1/4885KCNH2 1043/4885ADRB3 533/4885 |
| US-20120039999-A1 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
| US-20250073216-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1554/4885ADRB3 2864/4885 |
| US-20220241260-A9 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
| US-20150140087-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1623/4885ADRB3 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.